Associated tags: PDT, Fungal infection, Impetigo, Skin, Inc., BFRI, Pharmaceutical industry, COVID-19, Dermatology
Locations: AK, AUSTRALIA, NEW YORK CITY, GERMANY, HYATT, LEVERKUSEN, OHIO, WASHINGTON, BOSTON, NY, WOBURN, MASSACHUSETTS, US, UNITED STATES, CANADA, NEW YORK
Retrieved on:
Friday, December 16, 2022
Shareholder,
Grant Thornton International,
Security (finance),
Marketing,
LLP,
Skin,
PDT,
Impetigo,
BFRI,
Grant Thornton LLP,
COVID-19,
Pharmaceutical industry WOBURN, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced the final voting results from its 2022 Annual Meeting of Stockholders held on December 12, 2022.
Key Points:
- WOBURN, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced the final voting results from its 2022 Annual Meeting of Stockholders held on December 12, 2022.
- Stockholders re-elected board nominee Loretta M. Wedge to the Biofrontera Inc. Board of Directors as Class I director to serve until the 2025 Annual Meeting of Stockholders.
- Stockholders approved an amendment to the Biofrontera Inc. 2021 Omnibus Incentive Plan to increase the number of shares authorized for issuance under the plan by 2,589,800 shares.
- Stockholders ratified the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the 2022 fiscal year.
Retrieved on:
Wednesday, November 30, 2022
WOBURN, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the Company will be participating in Benchmarks 11th Annual Discovery One-on-One Investor Conference being held on December 1, 2022 in New York, NY.
Key Points:
- WOBURN, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the Company will be participating in Benchmarks 11th Annual Discovery One-on-One Investor Conference being held on December 1, 2022 in New York, NY.
- Erica Monaco, Chief Executive Officer, and Hermann Lbbert, Executive Chairman of Biofrontera Inc. will be meeting with registered investors in one-on-one meetings and small-group sessions.
- Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on PDT and topical antibiotics.
- The Companys licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.
Retrieved on:
Monday, November 28, 2022
Biofrontera is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products focused on the fields of photodynamic therapy and topical antibiotics.
Key Points:
- Biofrontera is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products focused on the fields of photodynamic therapy and topical antibiotics.
- In collaboration with healthcare providers, we are fully committed to advancing treatment options and patient care.
- Biofrontera, Inc. was founded in March 2015 to commercialize the FDA-approved flagship drug Ameluz (aminolevulinic acid hydrochloride) gel, 10%, in the United States.
- In 2019, Biofrontera Inc. expanded its U.S.-product portfolio with the FDA-approved drug Xepi (ozenoxacin) cream, 1%.
Retrieved on:
Monday, November 21, 2022
Marketing,
COVID-19,
Growth,
Patient,
Skin,
Scalp,
BFRI,
XL,
AK,
Acne,
Food,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
Face,
PDT,
FDA,
Impetigo,
Neck,
Clinical trial,
Extremities,
Trial of the century,
Safety,
Pharmaceutical industry This past weekend Biofrontera held an Investigator Meeting to train clinical investigators on the protocol for this photodynamic therapy (PDT) study and prepare for site initiation.
Key Points:
- This past weekend Biofrontera held an Investigator Meeting to train clinical investigators on the protocol for this photodynamic therapy (PDT) study and prepare for site initiation.
- Initially 11 clinical trial sites in the U.S. will participate, enrolling approximately 165 patients stratified by body region.
- This Phase 3 clinical study supports our strategy to gain market share by expanding the label for Ameluz-PDT beyond the treatment of AK on the face and scalp.
- A multicenter, randomized, double-blind Phase 2 clinical study evaluating the efficacy of Ameluz-PDT for the treatment of moderate-to-severe acne.
Retrieved on:
Monday, November 14, 2022
WOBURN, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced financial results for the three and nine months ended September 30, 2022 and provided a business update.
Retrieved on:
Thursday, November 10, 2022
WOBURN, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and nine months ended September 30, 2022 before the opening of the U.S. financial markets on Monday, November 14, 2022.
Key Points:
- WOBURN, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and nine months ended September 30, 2022 before the opening of the U.S. financial markets on Monday, November 14, 2022.
- The Company will hold a conference call that same day beginning at 11:00 a.m. Eastern time to discuss those results, provide a business update and answer questions.
Retrieved on:
Tuesday, November 8, 2022
GLOBE,
Dermatology,
Marketing,
Nasdaq,
Skin,
Impetigo,
Private Securities Litigation Reform Act,
Exercise,
SEC,
PDT,
Company,
BFRI,
Growth,
COVID-19,
Pharmaceutical industry These options were acquired in a private exchange agreement as announced on October 31, 2022, and were exercised at no additional cost.
Key Points:
- These options were acquired in a private exchange agreement as announced on October 31, 2022, and were exercised at no additional cost.
- Furthermore, Biofrontera Inc. announced the purchase of additional 1,601,318 shares of Biofrontera AG.
- As a result of this transaction, Biofrontera Inc. now owns 4,224,683 shares, corresponding to 7.45% of Biofrontera AGs outstanding ordinary shares.
- These statements include, but are not limited to, statements relating to the Companys relationship with Biofrontera AG, including the continued beneficial ownership in Biofrontera AG, and plans for ongoing collaboration.
PDT,
Marketing,
Intellectual property,
BFRI,
Impetigo,
Skin,
Private Securities Litigation Reform Act,
Dermatology,
U.S. Securities and Exchange Commission,
SEC,
Company,
GLOBE,
Growth,
Exercise,
COVID-19,
Nasdaq,
Security (finance),
Pharmaceutical industry The AG Options represent the right to acquire 2,623,365 ordinary shares of Biofrontera AG held by the shareholders, or approximately 4.63% of Biofrontera AGs outstanding ordinary shares, representing an exchange ratio of roughly 1.2 ordinary shares of Biofrontera Inc. for each option representing one Biofrontera AG share.
Key Points:
- The AG Options represent the right to acquire 2,623,365 ordinary shares of Biofrontera AG held by the shareholders, or approximately 4.63% of Biofrontera AGs outstanding ordinary shares, representing an exchange ratio of roughly 1.2 ordinary shares of Biofrontera Inc. for each option representing one Biofrontera AG share.
- As a result of this transaction, Biofrontera AGs shareholding in Biofrontera Inc. was reduced to 29.96%, further strengthening the independence of Biofrontera Inc. from its former parent company.
- The AG Options are immediately exercisable at no additional cost and the exercise period ends on November 30, 2022.
- At the same time, the transaction underscores the strength of our relationship with our former parent company Biofrontera AG.
Oregon Trail,
McKinsey & Company,
SEC,
FTI Consulting,
Skin,
Growth,
Dermatology,
MBA,
Nasdaq,
Private Securities Litigation Reform Act,
Corporate finance,
BFRI,
Company,
Marketing,
Financial management,
Impetigo,
Economics,
General Electric,
GLOBE,
Hotel manager,
PDT,
COVID-19,
BSBA,
Leadership,
Management,
Pharmaceutical industry,
Business WOBURN, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces the appointment of Fred Leffler as Chief Financial Officer, effective immediately.
Key Points:
- WOBURN, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces the appointment of Fred Leffler as Chief Financial Officer, effective immediately.
- Mr. Leffler is an experienced financial executive with 15 years of leadership, financial management, consultancy and operations experience across a range of private and public organizations, including growth-stage, private equity and Fortune 100 companies.
- We are delighted to welcome Fred as Chief Financial Officer during this important period of rapid growth at Biofrontera.
- I also look forward to broadening Biofronteras financial community relationships as we build upon our leadership position in the dermatology market, stated Mr. Leffler.
Retrieved on:
Thursday, October 20, 2022
A webcast of the presentation will be live and archived on the News & Events section of the company website.
Key Points:
- A webcast of the presentation will be live and archived on the News & Events section of the company website.
- Institutional investors registered for the conference who would like to meet with Erica Monaco and Hermann Lbbert, Executive Chairman of Biofrontera Inc., please contact LD Micro directly or the BFRI investor relations team.
- Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics.
- The Companys licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.
